Search

Your search keyword '"Schulze-Koops, Hendrik"' showing total 882 results

Search Constraints

Start Over You searched for: Author "Schulze-Koops, Hendrik" Remove constraint Author: "Schulze-Koops, Hendrik"
882 results on '"Schulze-Koops, Hendrik"'

Search Results

6. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

7. Fachspezifische Beurteilung des Berichts der Deutschen Gesellschaft für Innere Medizin (DGIM) zur Darstellung der Versorgungslandschaft im Bereich der Inneren Medizin in Deutschland durch die Deutsche Gesellschaft für Rheumatologie e.V. (DGRh)

9. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

11. The efficacy and safety of systemic corticosteroids as first line treatment for granulomatous lymphocytic interstitial lung disease

12. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial

13. Impact of Risk Factors on COVID‐19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID‐19 Global Rheumatology Alliance Registry

16. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

17. Radiographic Progression in Patients with Rheumatoid Arthritis in Clinical Remission or Low Disease Activity: Results from a Swiss National Registry (SCQM).

19. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

20. Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis

21. Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination

22. Immune checkpoint inhibitor–associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation

23. Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations

27. Aktualisierte Handlungsempfehlungen der Deutschen Gesellschaft für Rheumatologie für die Betreuung von Patienten mit entzündlich-rheumatischen Erkrankungen im Rahmen der SARS-CoV‑2/COVID‑19-Pandemie einschließlich Empfehlungen zur COVID‑19-Impfung

32. Does the Change of Weather Influence Disease Activity in Rheumatoid Arthritis Patients: Patients' Self-Assessment via WebApp.

33. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial

34. The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population—A comparison of two German registries

37. The Joint Vasculitis Registry in German-speaking countries (GeVas) – a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitis

45. Impact of Risk Factors on COVID‐19 Outcomes in Unvaccinated People with Rheumatic Diseases

50. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions:an update

Catalog

Books, media, physical & digital resources